Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit starkem Wachstum in den ersten neun Monaten 2021 – Ausblick für das Gesamtjahr erhöht

Basel, 20. Oktober 2021 Konzernverkäufe steigen um 8%1 zu konstanten Wechselkursen (CER); 6% in Schweizer FrankenVerkäufe der Division Pharma wachsen...
October 20, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Annonce événementielle selon l’art. 53 RC] Roche annonce une forte croissance de son chiffre d’affaires sur les neuf premiers mois de l’année – prévisions pour 2021 révisées à la hausse

Bâle, le 20 octobre 2021 Le chiffre d’affaires consolidé s’inscrit en hausse de 8%1 à taux de change constants (TCC) et de 6% en francs suisses.Le chiffre d’affaires de la division...
October 20, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in the first nine months – outlook for 2021 raised

Basel, 20 October 2021 Group sales up 8%1 at constant exchange rates (CER); 6% in Swiss francsPharmaceuticals Division sales grow 5% in the third quarter and...
October 15, 2021 12:30 ET | Source: F. Hoffmann-La Roche Ltd

US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer

Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant settingApproval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free...
October 15, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care

Artificial Intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment.Collaboration with...
October 14, 2021 01:03 ET | Source: F. Hoffmann-La Roche Ltd

New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder

New data demonstrate ENSPRYNG’s robust and sustained longer-term efficacy in preventing relapses in people with neuromyelitis optica spectrum disorder (NMOSD) More than 70% of people treated with...
October 14, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma

Short duration infusion of Gazyvaro® (obinutuzumab) is administered with a target infusion time of 90 minutes, compared to the current standard infusion time of approximately three to four...
October 13, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis

35% reduction in risk of needing a walking aid in relapsing multiple sclerosis (RMS) after 7.5 years vs. initiation 2 years later in Phase III open-label extension (OLE)29% reduction in 48-week...
October 08, 2021 11:40 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD)Gantenerumab is the first and only anti-amyloid antibody being investigated for subcutaneous...
October 05, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021

OCREVUS (ocrelizumab) data to show sustained reduction in disability progression through 8 years for primary progressive multiple sclerosis (PPMS) and 7.5 years for relapsing MS (RMS) Long-term safety...